Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine

Atacicept met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from ...
TipRanks on MSN

Vera Therapeutics reports ‘positive’ data from ORIGIN Phase 3 trial of atacicept

Vera Therapeutics (VERA) announced data from the ORIGIN Phase 3 trial of atacicept in IgA nephropathy were presented as a featured late-breaking ...

Vera Therapeutics (VERA) Rises on Strong Phase 3 IgAN Data and FDA Submission—Is Regulatory Execution the Next Key Hurdle?

Vera Therapeutics recently announced positive results from its Phase 3 ORIGIN trial of atacicept in adults with immunoglobulin A nephropathy (IgAN), highlighting a 42% reduction in proteinuria ...